Genentech, Inc.

Other

John B Lowe

Paula M Jardieu

Leonard G Presta

Henry Bernard Lowman

Bradley Richard Snedecor

Shahram Misaghi

Jo-Anne Hongo

Martin Vanderlaan

Ailen M Sanchez

Rajesh Vij

Terence Wong

X Christopher Yu

Susan C Fisher

Keyang Xu

David Tai Wai Fei

Saloumeh Kadkhodayan Fischer

Yanhong Li

Luna Liu

Mauricio Maia

The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.

Methods of making fucosylated and afucosylated forms of a protein

Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.

Method of treatment comprising purified recombinant IL-13 antibody

The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same.

Idiotypic antibodies and uses thereof

The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

Method for treating IgE-mediated disorders

The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-lgE and the target molecule is lgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

Anti-IgE antibodies

The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent

The present invention relates to a method for adjusting the affuinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

Anti-IgE antibodies and method of improving polypeptides

The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (,) the identification of aspartyl residues which are prone to isomerization; (,) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

Growing community of inventors

San Francisco, CA, United States of America

John B Lowe